omalizumab biosimilar (Shanghai Taiyin Biotech)

N/A

Report date: 2025/03/20 09:17:37

Base Information

Drug Nameomalizumab biosimilar (Shanghai Taiyin Biotech)
Drug Alias Namerecombinant anti-IgE humanized monoclonal antibody (Shanghai Taiyin Biotech)
ClassificationBiologics > Protein drugs > Recombinant proteinBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionImmunoglobulin E inhibitors
TargetsImmunoglobulin E
Therapy Area/IndicationsAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Taiyin Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Taiyin Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsAsthma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A